CELC (CELC) Stock Forecast: What Could Drive It in 2026
Short answer
What is actually driving CELC (CELC) right now is Gedatolisib FDA decision and launch: The July 17, 2026 PDUFA date for the HR+/HER2-/PIK3CA wild-type indication is the single largest catalyst. Revenue (TTM) is ~$0 (pre-revenue, clinical-stage). If that keeps playing out, the setup is favourable; the risk to it is celcuity is a pre-revenue, essentially single-asset company, so a delay or rejection at the PDUFA date, a label narrower than hoped, or disappointing later cohort data could sharply reduce the value the market assigns. No one can predict where CELC trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive CELC (CELC) higher?
1. Gedatolisib FDA decision and launch
The July 17, 2026 PDUFA date for the HR+/HER2-/PIK3CA wild-type indication is the single largest catalyst. An approval would convert Celcuity from a pre-revenue developer into a commercial-stage company, while the wider PIK3CA-mutant opportunity from VIKTORIA-1 could follow via a supplemental filing. Execution on manufacturing, pricing, and salesforce build-out then becomes the next test.
2. Differentiated pan-pathway mechanism
Gedatolisib blocks all four class I PI3K isoforms plus mTORC1 and mTORC2, aiming to close the adaptive-resistance loops that single-target drugs can leave open. In VIKTORIA-1 the combinations improved median progression-free survival by roughly 5.5 to 5.7 months versus alpelisib plus fulvestrant. If that profile holds in real-world use, it supports a premium position within the PAM-inhibitor class.
3. Label-expansion pipeline
Beyond the initial indication, the Phase 3 VIKTORIA-2 program is studying gedatolisib in first-line advanced breast cancer, including endocrine-sensitive and endocrine-resistant patients. Additional cohorts and combination regimens broaden the potential eligible population over time. Each readout is a discrete catalyst that can move the shares independent of the base indication.
What could weigh on CELC?
Celcuity is a pre-revenue, essentially single-asset company, so a delay or rejection at the PDUFA date, a label narrower than hoped, or disappointing later cohort data could sharply reduce the value the market assigns. It posted a net loss of roughly $52.8 million in the first quarter of 2026 and funds operations from cash plus a debt facility, so additional equity or debt financing (and potential dilution) is a live risk if a launch takes longer or costs more than planned. Even with approval, commercial uptake faces entrenched and newly approved competitors, payer and pricing pressure, and the operational challenge of a first launch. The stock has been volatile and can gap on single events, which is characteristic of clinical-stage biotech rather than a defect specific to this name.
Where CELC trades today
A forecast starts from where the stock actually is. These are CELC's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for CELC as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a CELC forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the CELC guide and whether CELC is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the CELC outlook
The bottom line: what is driving CELC (CELC) is Gedatolisib FDA decision and launch, with revenue (ttm) at ~$0 (pre-revenue, clinical-stage). If that keeps playing out the setup is favourable; the risk is celcuity is a pre-revenue, essentially single-asset company, so a delay or rejection at the PDUFA date, a label narrower than hoped, or disappointing later cohort data could sharply reduce the value the market assigns. No one can predict the price, so treat any CELC forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around CELC with Walnut
Use CELC as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for CELC (CELC)?
+
No one can reliably predict where CELC will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push CELC higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive CELC higher?
+
The main growth drivers are Gedatolisib FDA decision and launch; Differentiated pan-pathway mechanism; Label-expansion pipeline. Whether they play out is the real question, not a guaranteed path.
What are the risks to CELC?
+
Celcuity is a pre-revenue, essentially single-asset company, so a delay or rejection at the PDUFA date, a label narrower than hoped, or disappointing later cohort data could sharply reduce the value the market assigns. It posted a net loss of roughly $52.8 million in the first quarter of 2026 and funds operations from cash plus a debt facility, so additional equity or debt financing (and potential dilution) is a live risk if a launch takes longer or costs more than planned. Even with approval, commercial uptake faces entrenched and newly approved competitors, payer and pricing pressure, and the operational challenge of a first launch. The stock has been volatile and can gap on single events, which is characteristic of clinical-stage biotech rather than a defect specific to this name.
Will CELC stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. CELC's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is CELC a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the CELC "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.